PATH vs XGN · P/E 19, rev $1.61B vs rev $55.6M
Uipath Inc (PATH) versus Exagen Inc (XGN) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Exagen Inc (XGN) is a diagnostics & research company listed on US.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported XGN revenue for 2024-12-31 was $55.6M. Net income was -$15.1M. Revenue was up 5.9% from 2023-12-31 to 2024-12-31. XGN currently screens at market cap $154.1M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. XGN currently screens at market cap $154.1M.
Not investment advice. Open the PATH and XGN stock pages for the full models.
Not investment advice.